Literature DB >> 34695654

Executive function and dopamine response in Parkinson's disease freezing of gait.

Travis H Turner1, Federico Rodriguez-Porcel2, Philip Lee2, Katherine Teague2, Lisa Heidelberg2, Shonna Jenkins2, Gonzalo J Revuelta2.   

Abstract

BACKGROUND: This investigation examined whether aspects of attention and executive functioning differed between Parkinson's Disease (PD) patients with freezing of gait (FOG) based on responsiveness to dopamine. We also explored association of cognition with FOG severity and gait metrics.
METHODS: Fifty-four individuals with PD completed the study protocol: 17 without freezing (PDC), 23 with dopa-responsive FOG (RFOG), and 14 with dopa-unresponsive (URFOG). Standardized neuropsychological tests assessed attention (focused and sustained), psychomotor speed, and set-switching (time and errors). FOG severity was measured using the new FOG Questionnaire (nFOG-Q). Metrics from timed up and go (TUG) tasks were obtained while "on" and "off" dopamine, with and without dual cognitive tasks.
RESULTS: After controlling for clinical and demographic factors, analysis of covariance revealed a significant between-group difference for set-switching errors; planned contrasts revealed increased set-switching errors in URFOG relative to RFOG and PD control groups. Groups were not different in other cognitive domains. FOG severity was modestly associated with set-switching errors in RFOG but not URFOG. TUG performances while "on" were associated with set-switching errors in PD controls, and with focused attention in RFOG.
CONCLUSION: PD patients with dopa-unresponsive FOG are more prone to set-switching errors than those who respond to treatment. Furthermore, executive function appears relevant to FOG severity only in patients who show dopamine response. Together, these findings suggest disruption of a common dopamine-mediated pathway for FOG and ability to monitor rules while alternating cognitive processes. Consideration of dopa-response could be useful in characterizing cohorts and treating FOG in PD.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Dopa-response; Executive function; Freezing of gait; Parkinson

Mesh:

Substances:

Year:  2021        PMID: 34695654      PMCID: PMC8633152          DOI: 10.1016/j.parkreldis.2021.10.015

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  34 in total

1.  Evidence for subtypes of freezing of gait in Parkinson's disease.

Authors:  Kaylena A Ehgoetz Martens; James M Shine; Courtney C Walton; Matthew J Georgiades; Moran Gilat; Julie M Hall; Alana J Muller; Jennifer Y Y Szeto; Simon J G Lewis
Journal:  Mov Disord       Date:  2018-07       Impact factor: 10.338

2.  Alterations of functional and structural connectivity of freezing of gait in Parkinson's disease.

Authors:  Min Wang; Siming Jiang; Yongsheng Yuan; Li Zhang; Jian Ding; Jianwei Wang; Jiejin Zhang; Kezhong Zhang; Jie Wang
Journal:  J Neurol       Date:  2016-05-26       Impact factor: 4.849

3.  Increased on-state cortico-mesencephalic functional connectivity in Parkinson disease with freezing of gait.

Authors:  Daniel H Lench; Aaron Embry; Alyssa Hydar; Colleen A Hanlon; Gonzalo Revuelta
Journal:  Parkinsonism Relat Disord       Date:  2020-02-19       Impact factor: 4.891

4.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Authors:  Robert G Holloway; Ira Shoulson; Stanley Fahn; Karl Kieburtz; Anthony Lang; Kenneth Marek; Michael McDermott; John Seibyl; William Weiner; Bruno Musch; Cornelia Kamp; Mickie Welsh; Aileen Shinaman; Rajesh Pahwa; Lynn Barclay; Jean Hubble; Peter LeWitt; Janis Miyasaki; Oksana Suchowersky; Mark Stacy; David S Russell; Blair Ford; John Hammerstad; David Riley; David Standaert; Frederick Wooten; Stewart Factor; Joseph Jankovic; Farah Atassi; Roger Kurlan; Michel Panisset; Ali Rajput; Robert Rodnitzky; Cliff Shults; Giselle Petsinger; Cheryl Waters; Ronald Pfeiffer; Kevin Biglan; Leona Borchert; Amy Montgomery; Laura Sutherland; Carolyn Weeks; Maryan DeAngelis; Elspeth Sime; Susan Wood; Carol Pantella; Mary Harrigan; Barbara Fussell; Sandra Dillon; Barbara Alexander-Brown; Pamela Rainey; Marsha Tennis; Elke Rost-Ruffner; Diane Brown; Sharon Evans; Debra Berry; Jean Hall; Theresa Shirley; Judith Dobson; Deborah Fontaine; Brenda Pfeiffer; Alicia Brocht; Susan Bennett; Susan Daigneault; Karen Hodgeman; Carolynn O'Connell; Tori Ross; Karen Richard; Arthur Watts
Journal:  Arch Neurol       Date:  2004-07

5.  Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Emily J Henderson; Stephen R Lord; Matthew A Brodie; Daisy M Gaunt; Andrew D Lawrence; Jacqueline C T Close; A L Whone; Y Ben-Shlomo
Journal:  Lancet Neurol       Date:  2016-01-13       Impact factor: 44.182

6.  Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease.

Authors:  J D Schaafsma; Y Balash; T Gurevich; A L Bartels; J M Hausdorff; N Giladi
Journal:  Eur J Neurol       Date:  2003-07       Impact factor: 6.089

Review 7.  Dopamine Does Double Duty in Motivating Cognitive Effort.

Authors:  Andrew Westbrook; Todd S Braver
Journal:  Neuron       Date:  2016-02-17       Impact factor: 17.173

8.  Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.

Authors:  Santiago Perez-Lloret; Laurence Negre-Pages; Philippe Damier; Arnaud Delval; Pascal Derkinderen; Alain Destée; Wassilios G Meissner; Ludwig Schelosky; Francois Tison; Olivier Rascol
Journal:  JAMA Neurol       Date:  2014-07-01       Impact factor: 18.302

9.  The timed "Up & Go": a test of basic functional mobility for frail elderly persons.

Authors:  D Podsiadlo; S Richardson
Journal:  J Am Geriatr Soc       Date:  1991-02       Impact factor: 5.562

10.  Pilot study of atomoxetine in patients with Parkinson's disease and dopa-unresponsive Freezing of Gait.

Authors:  Gonzalo J Revuelta; Aaron Embry; Jordan J Elm; Chris Gregory; Amy Delambo; Steve Kautz; Vanessa K Hinson
Journal:  Transl Neurodegener       Date:  2015-12-10       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.